ISOFOL MEDICAL AB Isofol Medical AB (publ) announced that its Board of Directors has decided to appoint Roger Tell as acting CEO for the company, effective June 22, 2023. Dr. Roger Tell (b. 1965) has been active in Isofol since 2019 and is responsible for medical and scientific issues. He first held a position as Senior Vice President of Clinical Development and Chief Scientific Officer, thereafter, moving on to a role as Chief Medical Officer.
He joined Isofol from Aprea Therapeutics, where he was Vice President of Clinical Development. Prior to Aprea, he was an International Clinical Project Director at Servier in Suresnes, France. He has an extensive experience as an oncologist as well as an advisor to a number of biopharma companies, including Eli Lilly, Astra Zeneca and Merck Serono.
Dr. Tell holds a medical degree and a doctorate in experimental oncology from the Karolinska Institutet in Sweden, and he completed his residency in oncology at the Karolinska University Hospital. Roger Tell succeeds Thomas Andersson, who informed the board on 21 June that he was leaving his position as CEO.
